CA2072314C - Methodes de detection des metastases par l'amplification de l'acide nucleique - Google Patents

Methodes de detection des metastases par l'amplification de l'acide nucleique Download PDF

Info

Publication number
CA2072314C
CA2072314C CA002072314A CA2072314A CA2072314C CA 2072314 C CA2072314 C CA 2072314C CA 002072314 A CA002072314 A CA 002072314A CA 2072314 A CA2072314 A CA 2072314A CA 2072314 C CA2072314 C CA 2072314C
Authority
CA
Canada
Prior art keywords
seq
nos
carcinoma
target
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002072314A
Other languages
English (en)
Other versions
CA2072314A1 (fr
Inventor
Mark R. Green
Ernest S. Kawasaki
Robert E. Sobol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
University of California San Diego UCSD
Original Assignee
F Hoffmann La Roche AG
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24892478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2072314(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, University of California San Diego UCSD filed Critical F Hoffmann La Roche AG
Publication of CA2072314A1 publication Critical patent/CA2072314A1/fr
Application granted granted Critical
Publication of CA2072314C publication Critical patent/CA2072314C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002072314A 1991-06-26 1992-06-25 Methodes de detection des metastases par l'amplification de l'acide nucleique Expired - Lifetime CA2072314C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72006191A 1991-06-26 1991-06-26
US720,061 1991-06-26

Publications (2)

Publication Number Publication Date
CA2072314A1 CA2072314A1 (fr) 1992-12-27
CA2072314C true CA2072314C (fr) 2007-07-31

Family

ID=24892478

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002072314A Expired - Lifetime CA2072314C (fr) 1991-06-26 1992-06-25 Methodes de detection des metastases par l'amplification de l'acide nucleique

Country Status (9)

Country Link
US (2) US5543296A (fr)
EP (1) EP0520794B1 (fr)
JP (1) JP3898233B2 (fr)
AU (1) AU662906B2 (fr)
CA (1) CA2072314C (fr)
DE (1) DE69223284T2 (fr)
DK (1) DK0520794T3 (fr)
ES (1) ES2111047T3 (fr)
GR (1) GR3026153T3 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2148350A1 (fr) * 1992-10-29 1994-05-11 Carlo Croce Methodes de detection des micrometastases du cancer de la prostate
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5641672A (en) * 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5561041A (en) * 1993-11-12 1996-10-01 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection by analysis of sputum
US6235470B1 (en) 1993-11-12 2001-05-22 The Johns Hopkins University School Of Medicine Detection of neoplasia by analysis of saliva
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
CA2187775A1 (fr) * 1994-04-15 1995-10-26 Aaron E. Katz Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
WO1996021042A2 (fr) * 1995-01-04 1996-07-11 Trustees Of Boston University Amorces destinees a l'amplification pcr de sequences metastatiques
EP0871768B1 (fr) * 1995-03-17 2004-07-07 John Wayne Cancer Institute Depistage de metastases de melanome a l'aide d'un titrage par marqueurs multiples
EP0904397A4 (fr) * 1996-04-16 2003-01-29 Smithkline Beecham Corp Procede de detection de l'antigene specifique de la prostate utilise pour surveiller et diagnostiquer le cancer de la prostate
EP2264045B1 (fr) * 1996-08-14 2015-10-21 Life Technologies Corporation Composition pour l'amplification et pour la séquenciation de l'ADN
US6287822B1 (en) 1997-08-05 2001-09-11 Transgenomic, Inc. Mutation detection method
WO1998024935A1 (fr) * 1996-12-06 1998-06-11 Urocor, Inc. DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
DE69840669D1 (de) * 1997-04-10 2009-04-30 Stichting Katholieke Univ Pca3, pca3-gene und verfahren zu ihrer verwendung
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
DE19813788A1 (de) * 1998-03-27 1999-10-07 Deutsches Krebsforsch Nachweisverfahren für Tumorzellen
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
EP1084276A1 (fr) * 1998-06-10 2001-03-21 Memorec Medical Molecular Research Cologne Stoffel GmbH Support pour l'identification et l'etablissement en parallele de profils de transcription d'acides polynucleiques
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
EP1100903A1 (fr) * 1998-07-24 2001-05-23 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Gene pb 39 regule positivement dans le cancer de la prostate et utilisations dudit gene
US6455692B1 (en) 1998-08-04 2002-09-24 Transgenomic, Inc. Method of concentrating polynucleotides using MIPC
WO2000008212A1 (fr) * 1998-08-07 2000-02-17 Cellay, Llc Microgouttelettes de gel utilisees en analyse genetique
EP1151142A2 (fr) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Sequences d'acide nucleique permettant de detecter des marqueurs genetiques pour le cancer dans un echantillon biologique
EP1222266B1 (fr) 1999-09-29 2006-03-29 Diagnocure Inc. L'arnm du pca3 dans les tissus benins et malins de la prostate
US6203992B1 (en) 1999-10-15 2001-03-20 Abbott Laboratories Nucleic acid primers and probes for detecting tumor cells
US6902890B1 (en) * 1999-11-04 2005-06-07 Diadexus, Inc. Method of diagnosing monitoring, staging, imaging and treating cancer
WO2001034837A1 (fr) * 1999-11-12 2001-05-17 Limeart Limited Diagnostic et pronostic de cancer par detection de l'antigene tumoral 17-1a par rt-pcr
CA2404431C (fr) * 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c servant a deceler les cancers de l'estomac et de l'oesophage
AU2001253852A1 (en) * 2000-03-31 2001-10-15 Institut Gustave Roussy Preprocalcitonin as tumor rejection antigen precursor and uses thereof
US7829276B2 (en) * 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
CA2466896A1 (fr) 2001-09-06 2003-03-20 Adnagen Ag Procede et kit de diagnostic destines a la selection et/ou detection qualitative et/ou quantitative de cellules
WO2003044224A1 (fr) * 2001-11-22 2003-05-30 Adnagen Ag Kit de diagnostic, puce adn et methodes pour etablir le diagnostic ou effectuer le controle du traitement d'un cancer du testicule
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US7026120B2 (en) * 2002-04-15 2006-04-11 Abbott Laboratories Probes for detecting tumor cells
GR1004303B (el) * 2002-11-05 2003-07-30 Ελευθεριος Γεωργακοπουλος ΝΕΑ ΜΕΘΟΔΟΣ ΑΝΙΧΝΕΥΣΗΣ ΤΟΥ ΚΑΡΚΙΝΙΚΟΥ ΜΕΜΒΡΑΝΙΚΟΥ ΑΝΤΙΓΟΝΟΥ Ep-Cam ΚΑΙ ΠΡΟΣΔΙΟΡΙΣΜΟΣ ΚΥΚΛΟΦΟΡΟΥΝΤΩΝ ΜΙΚΡΟΜΕΤΑΣΤΑΤΙΚΩΝ ΚΑΡΚΙΝΙΚΩΝ ΚΥΤΤΑΡΩΝ ΣΤΟ ΠΕΡΙΦΕΡΙΚΟ ΑΙΜΑ ΑΣΘΕΝΩΝ (ΚΑΙ ΣΕ ΙΣΤΟΥΣ) ΜΕ ΚΑΡΚΙΝΟ ΕΠΙΘΗΛΙΑΚΗΣ ΠΡΟΕΛΕΥΣΗΣ
EP1572105B1 (fr) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection de micro metastases de melanomes et de cancer du sein dans des ganglions lymphatiques drainant des tumeurs incorporees dans de la paraffine par rt-pcr quantitative a l'aide de marqueurs multiples
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
EP1592809B1 (fr) 2003-02-07 2013-04-10 Diagnocure Inc. Procede de detection de cancer de la prostate dans un echantillon
WO2004094986A2 (fr) 2003-04-16 2004-11-04 Handylab, Inc. Systeme et procede de detection electrochimique de composes biologiques
EP2290073A3 (fr) 2004-05-28 2011-08-31 Asuragen, Inc. Procédés et compositions impliquant du microARN
ES2301268B1 (es) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
EP2302055B1 (fr) 2004-11-12 2014-08-27 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
CA2491067A1 (fr) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Rapport entre arnm dans les sediments urinaires ou l'urine en tant que marqueur pronostique du cancer de la prostate
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20070292882A1 (en) * 2006-06-16 2007-12-20 Sysmex Corporation Method and apparatus for detecting cancer cell
EP2041299A4 (fr) 2006-07-14 2010-01-13 Aviva Biosciences Corp Procedes et compositions servant a detecter des cellules rares dans un echantillon biologique
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073915A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
EP2104734A2 (fr) * 2006-12-08 2009-09-30 Asuragen, INC. Gènes et voies génétiques régulés par le mir-20 en tant que cibles en vue d'une intervention thérapeutique
CA2671270A1 (fr) * 2006-12-29 2008-07-17 Asuragen, Inc. Genes et voies regules par mir-16 utiles comme cibles pour intervention therapeutique
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (fr) 2007-09-14 2009-03-19 Asuragen, Inc. Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
WO2009052386A1 (fr) * 2007-10-18 2009-04-23 Asuragen, Inc. Micro arn exprimés différentiellement dans des maladies pulmonaires et leurs utilisations
WO2009070805A2 (fr) 2007-12-01 2009-06-04 Asuragen, Inc. Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
WO2009126726A1 (fr) * 2008-04-08 2009-10-15 Asuragen, Inc Procédés et compositions pour diagnostiquer et moduler le papillomavirus humain (hpv)
WO2009137807A2 (fr) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions et procédés liés à la modulation de miarn de néovascularisation ou d’angiogenèse
JP5585811B2 (ja) * 2009-01-23 2014-09-10 国立大学法人金沢大学 肺癌、肺癌合併ｌｅｍｓ及びｌｅｍｓの検査方法
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
KR101762340B1 (ko) 2015-12-09 2017-07-27 주식회사 포스코 수지 조성물 및 이를 이용한 흑색 수지 강판, 및 그 제조방법
GB201802312D0 (en) * 2018-02-13 2018-03-28 Vib Vzw Melanoma disease stratification

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1991009944A2 (fr) * 1989-12-22 1991-07-11 F.Hoffmann-La Roche Ag Transcriptases inverses obtenues a haute temperature
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US5024934A (en) * 1988-03-14 1991-06-18 The Board Of Regents, The University Of Texas System Detection of minimal numbers of neoplastic cells carrying DNA translocations by DNA sequence amplification
US5057410A (en) * 1988-08-05 1991-10-15 Cetus Corporation Chimeric messenger RNA detection methods
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification

Also Published As

Publication number Publication date
GR3026153T3 (en) 1998-05-29
EP0520794A1 (fr) 1992-12-30
CA2072314A1 (fr) 1992-12-27
DE69223284T2 (de) 1998-06-25
AU662906B2 (en) 1995-09-21
US5766888A (en) 1998-06-16
ES2111047T3 (es) 1998-03-01
DK0520794T3 (da) 1998-04-27
EP0520794B1 (fr) 1997-11-26
JPH05269000A (ja) 1993-10-19
JP3898233B2 (ja) 2007-03-28
US5543296A (en) 1996-08-06
DE69223284D1 (de) 1998-01-08
AU1846592A (en) 1993-01-07

Similar Documents

Publication Publication Date Title
CA2072314C (fr) Methodes de detection des metastases par l'amplification de l'acide nucleique
JP5133238B2 (ja) 遠隔サンプル由来のｄｎａ断片を提供する方法
US20230366034A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
EP0868529B1 (fr) Procede de detection des mutations ki-ras et son necessaire de mie en oeuvre
Rasmussen et al. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay
US5496699A (en) Detection of allele - specific mutagens
US20090226925A1 (en) Methods for Detecting Circulating Tumor Cells
Wood et al. Lack of the t (2; 5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
US20060204989A1 (en) Comparative analysis of extracellular RNA species
WO2000044940A2 (fr) Sequences d'acide nucleique permettant de detecter des marqueurs genetiques pour le cancer dans un echantillon biologique
US20090111097A1 (en) Comparative Analysis of Extracellular RNA Species
US20180252722A1 (en) PCR-based Method for Counting Circulating Tumor Cells
CA2451483C (fr) Methodes de detection et de surveillance du taux d'arn de cox-2 dans le plasma et le serum
EP1220954A2 (fr) Amorces et sondes d'acides nucleiques permettant de detecter des cellules tumorales
US7785842B2 (en) Comparative analysis of extracellular RNA species
Ruschenburg et al. MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter.
Tbakhi et al. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders
CN116536419A (zh) 检测alk基因融合的引物、探针及其试剂盒
WO2001053535A2 (fr) Procede de detection de croissance ou de proliferation cellulaire neoplasique, hyperplasique, cytologiquement dysplasique et/ou premaligne
JP6871271B2 (ja) Ｄｌｂｃｌを分類するための方法および組成物
US8043835B1 (en) Methods for detecting and monitoring cancer using extracellular RNA
JP2020534817A (ja) 短い核酸の多重検出
WO2004048608A1 (fr) Nouvelle methode rt-pcr en temps reel pour une detection sensible de plusieurs transcrits geniques mage
KR20080073087A (ko) 신경모세포종 세포의 검출
EP1379697A4 (fr) Detection d'acides nucleiques a des fins diagnostiques

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry